Cerevel Therapeutics Holdings, Inc.

The fourth quarter of 2024 was not without setbacks for AbbVie, which took a $3.5bn impairment against the value of its 2023 buyout of Cerevel after a Phase II failure in schizophrenia, but the pharma

It did not take long for predictions of higher-priced merger-and-acquisition activity in 2025 to come true as Johnson & Johnson’s proposed $14.6bn buyout of Intra-Cellular and its rising neuropsyc

Whereas the primary driver of AbbVie’s $8.7bn acquisition of Cerevel, the schizophrenia candidate emraclidine, has been a disappointment, the pharma racked up a third positive Phase III readout for th

Since its inception in 2013, AbbVie has had a consistent sales and earnings story – its top-selling drug, and at times topping the entire industry, has been the anti-TNF therapeutic Humira (adalimumab